Deep Dive: FDA's RWE Guidance

Real-world data does not become regulatory evidence simply because it is large, current, or readily available.

FDA’s December 2025 final guidance, Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices, supersedes the 2017 guidance and provides a more detailed framework for determining when real-world data can generate evidence suitable for a medical device regulatory decision.

One important change is FDA’s recognition that a sponsor’s inability to obtain participant-level data does not automatically prevent the Agency from evaluating the evidence. But this flexibility does not lower the evidentiary bar. Sponsors must explain the limits of data access and demonstrate—through rigorous, traceable documentation—that the data and resulting analysis are credible.

Key highlights covered in the audio:

* The difference between real-world data and real-world evidence

* How FDA evaluates relevance, including data availability, timeliness, and generalizability

* How FDA evaluates reliability, including data provenance, completeness, consistency, quality controls, and traceability

* Why protocols and analysis plans should be established before reviewing outcomes

* How sponsors should address bias, confounding, missing data, and data-linkage methods

* New documentation recommendations for cover letters, study protocols, reports, and eSTAR submissions

* When studies using routinely collected data may—or may not—require an IDE

Keywords: